Effects of Postnatal Caffeine Exposure on Absence Epilepsy and Comorbid Depression: Results of a Study in WAG/Rij Rats.
WAG/Rij rats
caffeine
chronic absence seizure
depression
Journal
Brain sciences
ISSN: 2076-3425
Titre abrégé: Brain Sci
Pays: Switzerland
ID NLM: 101598646
Informations de publication
Date de publication:
08 Mar 2022
08 Mar 2022
Historique:
received:
22
01
2022
revised:
03
03
2022
accepted:
06
03
2022
entrez:
25
3
2022
pubmed:
26
3
2022
medline:
26
3
2022
Statut:
epublish
Résumé
The present study aims to investigate effect of early caffeine exposure on epileptogenesis and occurrence of absence seizures and comorbid depression in adulthood. For this purpose, Wistar Albino Glaxo from Rijswijk (WAG/Rij) rats were enrolled in a control and two experimental groups on the 7th day after the delivery. The rats in experimental groups received either 10 or 20 mg/kg caffeine subcutaneously while animals in control group had subcutaneous injections of 0.9% saline. The injections started at postnatal day 7 (PND7) and were continued each day for 5 days. At 6-7 months of age, electroencephalogram (EEG) recordings and behavioral recordings in the forced swimming test, sucrose consumption/preference test and locomotor activity test were carried out. At 6 months of age, 10 mg/kg and 20 mg/kg caffeine-treated WAG/Rij rats showed increased immobility latency and active swimming duration in forced swimming test when compared with the untreated controls. In addition, 20 mg/kg caffeine treatment decreased immobility time. In sucrose preference/consumption tests, WAG/Rij rats in 10 mg/kg caffeine group demonstrated higher sucrose consumption and preference compared to untreated controls. The rats treated with 20 mg/kg caffeine showed higher sucrose preference compared to control rats. The exploratory activity of rats in the 10 mg/kg caffeine-treated group was found to be higher than in the 20 mg/kg caffeine-treated and control groups in the locomotor activity test. At 7 months of age, caffeine-treated animals showed a decreased spike-wave discharge (SWD) number compared to the control animals. These results indicate that postnatal caffeine treatment may decrease the number of seizure and depression-like behaviors in WAG/Rij rats in later life. Caffeine blockade of adenosine receptors during the early developmental period may have beneficial effects in reducing seizure frequency and depression-like behaviors in WAG/Rij rat model.
Identifiants
pubmed: 35326317
pii: brainsci12030361
doi: 10.3390/brainsci12030361
pmc: PMC8946037
pii:
doi:
Types de publication
Journal Article
Langues
eng
Subventions
Organisme : University of Kocaeli
ID : 2017/026
Références
Front Pharmacol. 2018 Jun 01;9:526
pubmed: 29910727
Brain Res Bull. 2014 May;104:27-35
pubmed: 24727007
Neuropharmacology. 2020 May 1;167:107735
pubmed: 31377200
Genes Brain Behav. 2018 Sep;17(7):e12477
pubmed: 29604188
Neurosci Lett. 2004 Jan 23;355(1-2):21-4
pubmed: 14729225
Front Mol Neurosci. 2017 Jul 25;10:235
pubmed: 28790891
Epilepsy Res. 2010 Feb;88(2-3):231-8
pubmed: 20034762
J Neurochem. 2010 Jan;112(2):453-62
pubmed: 19878534
Int J Dev Neurosci. 2015 Dec;47(Pt B):192-7
pubmed: 26449401
Pediatrics. 2005 Nov;116(5):1089-94
pubmed: 16263994
Nature. 2001 Dec 20-27;414(6866):916-20
pubmed: 11780065
Nat Rev Neurosci. 2013 May;14(5):337-49
pubmed: 23595016
J Neurosci Methods. 2018 Dec 1;310:54-62
pubmed: 29857008
J Neuroimmunol. 2019 Jan 15;326:1-8
pubmed: 30423516
Psychol Med. 2018 Jul;48(9):1560-1571
pubmed: 29173244
Cell Reprogram. 2021 Apr;23(2):57-72
pubmed: 33861641
Epilepsia. 2010 Jan;51(1):146-60
pubmed: 19674046
Mol Neurobiol. 2020 Jan;57(1):408-421
pubmed: 31368023
Neuropharmacology. 2020 May 1;167:107741
pubmed: 31419398
Dokl Biol Sci. 2017 Mar;473(1):39-42
pubmed: 28508204
Pharmacol Res. 2021 Jan;163:105363
pubmed: 33285234
Front Cell Neurosci. 2014 Oct 02;8:312
pubmed: 25324724
Int Rev Neurobiol. 2014;119:373-93
pubmed: 25175973
Behav Pharmacol. 2012 Aug;23(4):339-47
pubmed: 22785384
Epilepsia. 2005 Sep;46(9):1401-6
pubmed: 16146434
Pharmacol Biochem Behav. 2016 Apr;143:26-33
pubmed: 26850920
Neurology. 2003 Dec 9;61(11 Suppl 6):S82-7
pubmed: 14663017
Eur J Neurosci. 2009 Sep;30(6):1023-35
pubmed: 19723291
Seizure. 2009 Sep;18(7):463-9
pubmed: 19493686
Epilepsy Res. 2020 Sep;165:106379
pubmed: 32526640
Neurosci Lett. 1986 Oct 20;70(3):393-7
pubmed: 3095713
Brain Res Dev Brain Res. 1995 Oct 27;89(1):124-8
pubmed: 8575085
J Neurosci Methods. 2016 Feb 15;260:175-84
pubmed: 26343323
Neurotherapeutics. 2014 Apr;11(2):231-41
pubmed: 24492975
Int J Mol Sci. 2020 Jul 04;21(13):
pubmed: 32635541
Epilepsy Behav. 2018 Mar;80:37-47
pubmed: 29414557
Neurobiol Dis. 2014 Dec;72 Pt B:167-79
pubmed: 25132554
Neurosci Biobehav Rev. 1999 Mar;23(4):563-76
pubmed: 10073894
Neurotherapeutics. 2017 Oct;14(4):1134-1147
pubmed: 28653281
Brain Neurosci Adv. 2018 Dec 6;2:2398212818817494
pubmed: 32166165
Curr Neurol Neurosci Rep. 2019 May 14;19(6):32
pubmed: 31089986
Naunyn Schmiedebergs Arch Pharmacol. 1993 Apr;347(4):407-14
pubmed: 8510768
Behav Brain Res. 2005 May 7;160(1):99-106
pubmed: 15836904
Front Neurol. 2020 Apr 28;11:245
pubmed: 32411068
Acta Neurol Belg. 2013 Dec;113(4):493-500
pubmed: 23864335
Brain Res. 2007 May 30;1150:32-9
pubmed: 17439812
Front Behav Neurosci. 2020 Jul 23;14:132
pubmed: 32792925
Sci Transl Med. 2013 Aug 7;5(197):197ra104
pubmed: 23926202
J Clin Invest. 2013 Aug;123(8):3552-63
pubmed: 23863710
Seizure. 2017 Jan;44:53-57
pubmed: 27986418
Epilepsia. 1981 Feb;22(1):85-94
pubmed: 7472302
Brain Res Bull. 2019 Nov;153:133-142
pubmed: 31470253
Behav Brain Res. 2006 Jan 6;166(1):9-18
pubmed: 16183145
Epilepsy Res. 2015 Feb;110:105-14
pubmed: 25616462